JP2024529298A - Ｉｋｚｆ２を調節するアリール化合物及び医薬組成物 - Google Patents

Ｉｋｚｆ２を調節するアリール化合物及び医薬組成物 Download PDF

Info

Publication number
JP2024529298A
JP2024529298A JP2024500179A JP2024500179A JP2024529298A JP 2024529298 A JP2024529298 A JP 2024529298A JP 2024500179 A JP2024500179 A JP 2024500179A JP 2024500179 A JP2024500179 A JP 2024500179A JP 2024529298 A JP2024529298 A JP 2024529298A
Authority
JP
Japan
Prior art keywords
pharma
tautomer
stereoisomer
solvate
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024500179A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024529298A5 (https=
Inventor
ポンユー ヤン
サイモン ベイリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plexium Inc
Original Assignee
Plexium Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plexium Inc filed Critical Plexium Inc
Publication of JP2024529298A publication Critical patent/JP2024529298A/ja
Publication of JP2024529298A5 publication Critical patent/JP2024529298A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2024500179A 2021-07-09 2022-07-08 Ｉｋｚｆ２を調節するアリール化合物及び医薬組成物 Pending JP2024529298A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163220323P 2021-07-09 2021-07-09
US63/220,323 2021-07-09
US202263314992P 2022-02-28 2022-02-28
US63/314,992 2022-02-28
PCT/US2022/036511 WO2023283425A1 (en) 2021-07-09 2022-07-08 Aryl compounds and pharmaceutical compositions that modulate ikzf2

Publications (2)

Publication Number Publication Date
JP2024529298A true JP2024529298A (ja) 2024-08-06
JP2024529298A5 JP2024529298A5 (https=) 2025-07-15

Family

ID=82703117

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024500179A Pending JP2024529298A (ja) 2021-07-09 2022-07-08 Ｉｋｚｆ２を調節するアリール化合物及び医薬組成物

Country Status (10)

Country Link
US (2) US11878968B2 (https=)
EP (1) EP4367112A1 (https=)
JP (1) JP2024529298A (https=)
KR (1) KR20240035820A (https=)
AU (1) AU2022306297A1 (https=)
CA (1) CA3226162A1 (https=)
IL (1) IL309666A (https=)
MX (1) MX2024000313A (https=)
TW (1) TW202317546A (https=)
WO (1) WO2023283425A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12122764B2 (en) 2021-12-22 2024-10-22 Gilead Sciences, Inc. IKAROS zinc finger family degraders and uses thereof
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN121866057A (zh) * 2023-07-27 2026-04-14 普莱克斯姆公司 调节ikzf2的化合物的盐及固体形式
KR102834908B1 (ko) * 2023-09-02 2025-07-16 브리스톨-마이어스 스큅 컴퍼니 치환된 페닐 옥소옥사졸릴 피페리딘 디온 화합물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020012334A1 (en) * 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
WO2020012337A1 (en) * 2018-07-10 2020-01-16 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases

Family Cites Families (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6250751A (ja) 1985-08-29 1987-03-05 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
AU653024B2 (en) 1991-05-30 1994-09-15 Novartis Ag Substituted diaminophthalimides and analogues
HUT67665A (en) 1991-11-05 1995-04-28 Smithkline Beckman Corp Indane and indene deriv.s as endothelin receptor antagonists, pharmaceutical compn.s contg. them and process for prepg. them
ATE188379T1 (de) 1992-10-14 2000-01-15 Merck & Co Inc Fibrinogenrezeptor-antagonisten
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
ATE224884T1 (de) 1996-07-01 2002-10-15 Schering Corp Muscarin-antagonisten
EP0963755A3 (en) 1998-04-16 2001-03-14 Pfizer Products Inc. Use of benzopyranes for preventing allograft rejection
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
YU86801A (sh) 1999-06-10 2004-07-15 Warner-Lambert Company Izoindol derivati korisni u inhibiciji agregacije amiloidnih proteina i snimanju amiloidnih naslaga
EP1255750A1 (en) 2000-02-01 2002-11-13 Millenium Pharmaceuticals, Inc. INDOLE AND BENZIMIDAZOLE INHIBITORS OF FACTOR Xa
DE10006453A1 (de) 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
HUP0301501A2 (hu) 2000-06-23 2003-08-28 Novo Nordisk A/S Glükagon antaagonista/inverz agonista vegyületek, ezeket tartalmazó gyógyászati készítmények, valamint a vegyületek alkalmazása gyógyászati készítmények előállítására
ATE420869T1 (de) 2000-10-05 2009-01-15 Takeda Pharmaceutical Promotoren zur proliferation und differenzierung von stammzellen und/oder vorstufen von neuronenzellen
WO2002040445A1 (en) 2000-11-17 2002-05-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
WO2002060426A2 (en) 2001-01-03 2002-08-08 President And Fellows Of Harvard College Compounds regulating cell proliferation and differentiation
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
WO2002072549A1 (en) 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
AU2002349705A1 (en) 2001-12-03 2003-06-17 Japan Tobacco Inc. Azole compound and medicinal use thereof
WO2003074046A1 (en) 2002-03-01 2003-09-12 Takeda Chemical Industries, Ltd. Antidepressant
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
KR100984595B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
AU2003216660A1 (en) 2002-04-26 2003-11-10 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
FR2841554B1 (fr) 2002-07-01 2008-01-18 Commissariat Energie Atomique Composes de maleimides marques, leur procede de preparation et leur utilisation pour le marquage de macromolecules
DE10238002A1 (de) 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
GB2396154B (en) 2002-10-15 2007-02-28 Merck Patent Gmbh 4,5-Dicyanoimidazole derivatives and their use in liquid crystal media and liquid crystal devices
EP1562931A2 (en) 2002-10-25 2005-08-17 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
US7622592B2 (en) 2002-11-01 2009-11-24 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
WO2004063147A1 (en) 2003-01-10 2004-07-29 Novo Nordisk A/S Salts and solvates of glucagon antagonists
EP1594842A1 (en) 2003-02-22 2005-11-16 MERCK PATENT GmbH Cyanopyridone derivatives as liquid crystals
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004096210A1 (en) 2003-05-01 2004-11-11 Glaxo Group Limited Acylated indoline and tetrahydroquinoline derivatives as hcv inhibitors
EP1644367B1 (en) 2003-05-19 2015-10-14 Novartis AG Immunosuppressant compounds and compositions
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
JP2005053058A (ja) 2003-08-04 2005-03-03 Fuji Photo Film Co Ltd 光情報記録媒体および情報記録方法
US20050075358A1 (en) 2003-10-06 2005-04-07 Carboni Joan M. Methods for treating IGF1R-inhibitor induced hyperglycemia
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
BRPI0418212A (pt) 2003-12-29 2007-04-27 Banyu Pharma Co Ltd composto ou um sal deste farmaceuticamente aceitável, ativador da glicocinase, e, medicamentos para a terapia e/ou prevenção da diabete, e da obesidade
CA2555313A1 (en) 2004-02-06 2005-08-18 Insight Biopharmaceuticals Ltd Heparanase inhibitors and uses thereof
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
US20070276020A1 (en) 2004-03-08 2007-11-29 Boykin David W Dicationic Compounds For Activity Against Trichomonas Vaginalis
US20080096935A1 (en) 2004-10-25 2008-04-24 Pinkerton Anthony B Heterocyclic Indanone Potentiators of Metabotropic Glutamate Receptors
RU2398773C2 (ru) 2004-11-02 2010-09-10 Баниу Фармасьютикал Ко., Лтд. Арилоксизамещенное производное бензимидазола
US20090306052A1 (en) 2004-12-07 2009-12-10 Glaxo Group Limited Indenyl derivatives and use thereof for the treatment of neurological disorders
CA2598531A1 (en) 2005-02-24 2006-08-31 Merck & Co., Inc. Benzazole potentiators of metabotropic glutamate receptors
EP2363128B1 (en) 2005-03-11 2016-02-17 Vertex Pharmaceuticals Incorporated Indole modulators of ATP-binding cassette transporters
US20060247263A1 (en) 2005-04-19 2006-11-02 Amgen Inc. Substituted heterocyclic compounds and methods of use
AU2006202040A1 (en) 2005-05-20 2006-12-07 Reto Brun Novel biochalcophenes and their prodrugs as antiprotozoal agents
EP1905769B1 (en) 2005-07-13 2017-03-29 Msd K.K. Heterocycle-substituted benzimidazole derivative
JP2007022937A (ja) 2005-07-13 2007-02-01 Banyu Pharmaceut Co Ltd ヘテロ環置換ベンズイミダゾール誘導体
WO2007117262A2 (en) 2005-07-29 2007-10-18 Athersys, Inc. Culture of non-embryonic cells at high cell density
US20080194021A1 (en) 2005-07-29 2008-08-14 Mays Robert W Use of a Gsk-3 Inhibitor to Maintain Potency of Culture Cells
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
US20090291983A1 (en) 2006-07-12 2009-11-26 Astrazeneca Ab 3-Oxoisoindoline-1-Carboxamide Derivatives as Analgesic Agents
WO2008029168A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
AR063311A1 (es) 2006-10-18 2009-01-21 Novartis Ag Compuestos organicos
HRP20131103T1 (hr) 2007-04-20 2013-12-20 The Research Foundation Of State University Of New York Benzimidazoli i njihovi farmaceutski pripravci
US7858803B2 (en) 2007-04-27 2010-12-28 The General Hospital Corporation Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders
KR20090007075A (ko) 2007-07-13 2009-01-16 제일모직주식회사 유기발광소자용 화합물 및 이를 이용한 유기전자소자
ES2424214T3 (es) 2007-08-27 2013-09-30 Siga Technologies, Inc. Medicamentos antivirales para el tratamiento de una infección por Arenavirus
WO2009112445A1 (en) 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
EP2110374A1 (en) 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
KR101367514B1 (ko) 2008-07-11 2014-02-27 주식회사 엘지화학 신규한 안트라센 유도체 및 이를 이용한 유기전자소자
SG172352A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
US9278922B2 (en) 2009-04-15 2016-03-08 Abbvie Inc. Anti-viral compounds
JP2012528195A (ja) 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション Ｃ型肝炎などの疾患を処置するための３つの結合アリール部分で構成された抗菌性化合物
WO2010148006A1 (en) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
US8455516B2 (en) 2010-01-15 2013-06-04 Touro University HIV-1 fusion inhibitors and methods
WO2011116356A2 (en) 2010-03-19 2011-09-22 Sanford-Burnham Medical Research Institute Positive allosteric modulators of group ii mglurs
EP2371828B1 (en) 2010-04-01 2018-01-10 Samsung Display Co., Ltd. Condensed-Cyclic Compound and Organic Light-Emitting Device Including the Same
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
KR20130059400A (ko) 2010-08-25 2013-06-05 (주)네오팜 신규한 헤테로고리 화합물 및 이를 이용한 염증성 질환 치료용 조성물
CA2809836C (en) 2010-09-01 2019-01-15 Gilead Connecticut, Inc. Pyridinones/pyrazinones, method of making, and method of use thereof for the treatment of disorders mediated by bruton's tyrosine kinase
US8975260B2 (en) 2010-09-01 2015-03-10 Genetech, Inc Pyridazinones, method of making, and method of use thereof
US9381177B2 (en) 2010-10-01 2016-07-05 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
SG189019A1 (en) 2010-10-18 2013-05-31 Cerenis Therapeutics Holding Sa Compounds, compositions and methods useful for cholesterol mobilisation
WO2012075381A1 (en) 2010-12-03 2012-06-07 Epizyme, Inc. Substituted purine and 7 - deazapurine compounds as modulators of epigenetic enzymes
JP5728921B2 (ja) 2010-12-10 2015-06-03 コニカミノルタ株式会社 光学フィルム、及びそれを用いた偏光板、液晶表示装置
EP2651928A4 (en) 2010-12-15 2014-06-18 Abbvie Inc ANTI-VIRAL COMPOUNDS
TWI574687B (zh) 2011-01-03 2017-03-21 古利斯股份有限公司 具有鋅結合部份之刺蝟拮抗劑
KR101284174B1 (ko) 2011-01-05 2013-07-09 한국과학기술연구원 디페닐 유도체를 포함하는 항균제
GB201103762D0 (en) 2011-03-07 2011-04-20 Vib Vzw Means and methods for the treatment of neurodegenerative disorders
CN102675194B (zh) 2011-03-16 2014-10-01 中国人民解放军军事医学科学院毒物药物研究所 含肟类的氨基衍生物、其药物组合物、其制备方法及用途
WO2012130829A1 (en) 2011-03-29 2012-10-04 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh New boranophosphate analogues of cyclic nucleotides
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2012162580A2 (en) 2011-05-26 2012-11-29 Abbvie Inc Anti-viral compounds
WO2012167053A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
JP6040677B2 (ja) 2011-09-29 2016-12-07 東洋インキＳｃホールディングス株式会社 太陽電池封止材用樹脂組成物
US9730913B2 (en) 2011-10-13 2017-08-15 The Johns Hopkins University High affinity beta lactamase inhibitors
WO2013059278A2 (en) 2011-10-17 2013-04-25 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
KR101821256B1 (ko) 2011-11-03 2018-01-24 삼성디스플레이 주식회사 헤테로고리 화합물 및 이를 포함하는 유기 전계 발광 소자
WO2013106409A1 (en) 2012-01-10 2013-07-18 Merck Patent Gmbh Benzamide derivatives as modulators of the follicle stimulating hormone
WO2013116823A1 (en) 2012-02-02 2013-08-08 The Research Foundation Of State University Of New York Benzimidazoles and uses thereof
WO2013118855A1 (ja) 2012-02-09 2013-08-15 塩野義製薬株式会社 複素環および炭素環誘導体
CA2868302A1 (en) 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
JP2015167150A (ja) 2012-05-28 2015-09-24 出光興産株式会社 有機エレクトロルミネッセンス素子
WO2013182519A1 (en) 2012-06-04 2013-12-12 Universitaet Basel Combination of lysosomotropic or autophagy modulating agents and a gsk-3 inhibitor for treatment of cancer
US20150336985A1 (en) 2012-06-22 2015-11-26 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
US9419231B2 (en) 2012-07-25 2016-08-16 Idemitsu Kosan Co., Ltd. Organic electroluminescence device
EP3563849A3 (en) 2012-10-25 2020-02-12 The General Hospital Corporation Combination therapies for the treatment of alzheimer's disease and related disorders
KR20140111214A (ko) 2013-03-08 2014-09-18 에스에프씨 주식회사 유기발광 화합물 및 이를 포함하는 유기전계발광소자
JP2016517434A (ja) 2013-03-14 2016-06-16 エピザイム，インコーポレイティド 癌を処置するための併用療法
KR101676416B1 (ko) 2013-05-31 2016-11-15 제일모직 주식회사 유기 화합물, 유기 광전자 소자 및 표시 장치
TW201534597A (zh) 2013-06-20 2015-09-16 Ab Science 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
WO2015001726A1 (ja) 2013-07-03 2015-01-08 保土谷化学工業株式会社 有機エレクトロルミネッセンス素子
CN104592211B (zh) 2013-10-31 2018-10-16 广东东阳光药业有限公司 联苯类化合物及其用途
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
TWI547486B (zh) 2013-12-12 2016-09-01 中央研究院 用於醣類分析及合成的化合物及方法
WO2015161016A1 (en) 2014-04-17 2015-10-22 Merck Sharp & Dohme Corp. Bicyclic cgrp receptor antagonists
WO2015187850A2 (en) 2014-06-03 2015-12-10 Duke University Compounds and methods for treatment of ocular disorders
WO2015193506A1 (en) 2014-06-20 2015-12-23 Institut Pasteur Korea Anti-infective compounds
KR102494596B1 (ko) 2014-07-31 2023-01-31 재단법인 한국파스퇴르연구소 2-아미노-벤즈이미다졸 유도체 및 5-리폭시게나아제 및/또는 프로스타글란딘 e 합성효소 억제제로서의 이들의 용도
EA035646B1 (ru) 2014-08-29 2020-07-21 Сиэйчдиай Фаундэйшн, Инк. Зонды для визуализации белка хантингтина
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EA036272B1 (ru) 2015-04-08 2020-10-21 БЁРИНГЕР ИНГЕЛЬХАЙМ ЭНИМАЛ ХЕЛТ ЮЭсЭй ИНК. Инъецируемые препараты замедленного высвобождения, содержащие изоксазолиновое действующее вещество, способы и применение
KR101882221B1 (ko) 2015-04-29 2018-07-26 희성소재 (주) 헤테로고리 화합물 및 이를 이용한 유기 발광 소자
KR102002034B1 (ko) 2015-07-09 2019-07-22 에스에프씨주식회사 고효율과 장수명을 갖는 유기 발광 소자
WO2017039318A1 (en) 2015-09-01 2017-03-09 Kainos Medicine, Inc. Benzimidazole derivatives for dna methylation inhibitors
AU2016319125B2 (en) 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JP2018535190A (ja) 2015-09-16 2018-11-29 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ Ｐ５３欠損細胞の治療におけるニクロサミドの使用
WO2017051319A1 (en) 2015-09-21 2017-03-30 Glenmark Pharmaceuticals S.A. Aryl and heteroaryl ether compounds as ror gamma modulators
WO2017117449A1 (en) 2015-12-29 2017-07-06 Sabic Global Technologies B.V. Methods for the manufacture of an aromatic bisimide and a polyetherimide
SG11201808728QA (en) 2016-04-06 2018-11-29 Univ Michigan Regents Mdm2 protein degraders
US10759808B2 (en) 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
KR102545509B1 (ko) 2016-06-02 2023-06-21 삼성디스플레이 주식회사 다환 화합물 및 이를 포함하는 유기 전계 발광 소자
WO2018010142A1 (en) 2016-07-14 2018-01-18 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
CA3036834A1 (en) 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-oxazepines as bet protein degraders
CA3036841A1 (en) 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet protein degraders
CN110506039A (zh) 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
CN107973742A (zh) 2016-10-24 2018-05-01 重庆文理学院 制备3-吲哚酮类化合物的方法
US10738007B2 (en) 2016-10-24 2020-08-11 Translation Drug Development, LLC Amide compounds as kinase inhibitors, compositions and methods of treatment
JP6948398B2 (ja) 2016-10-24 2021-10-13 トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー キナーゼ阻害剤としてのアミド化合物
CN108003089A (zh) 2016-10-27 2018-05-08 江苏三月光电科技有限公司 以蒽为核心化合物及有机电致发光器件和其应用
KR102673117B1 (ko) 2016-12-06 2024-06-07 솔루스첨단소재 주식회사 유기 화합물 및 이를 이용한 유기 전계 발광 소자
JP2020505327A (ja) 2016-12-23 2020-02-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
IL312367A (en) 2017-01-31 2024-06-01 Arvinas Operations Inc Cereblon ligands and bifunctional compounds comprising the same
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof
IT201700039562A1 (it) 2017-04-10 2018-10-10 Univ Pisa Derivati isoindolinici quali attivatori di ampk
CN108689942B (zh) 2017-04-11 2023-06-09 广东东阳光药业有限公司 含氮双环化合物及其制备方法和用途
US11021471B2 (en) 2017-05-10 2021-06-01 Forge Therapeutics, Inc. Antibacterial compounds
JP7311228B2 (ja) 2017-06-30 2023-07-19 ベイジン タイド ファーマシューティカル カンパニー リミテッド Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
WO2019023651A2 (en) 2017-07-28 2019-01-31 Massachusetts Institute Of Technology MODULATORS OF THE SMALL MOLECULE ANDROGEN RECEPTOR
WO2019032671A1 (en) 2017-08-10 2019-02-14 Coty Inc. OXIDIZING COLORED COUPLERS COMPRISING NEW AZOMETHINIC AUXOCHROMES AND COLORANTS SUBSTITUENTS AND THEIR LEUKODIFIED FORMS
JP2019034904A (ja) 2017-08-17 2019-03-07 保土谷化学工業株式会社 芳香族炭化水素基と２つのフタルイミド基を有する化合物および有機エレクトロルミネッセンス素子
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
US10597382B2 (en) 2017-08-28 2020-03-24 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US11177446B2 (en) 2017-09-14 2021-11-16 Beijing Summer Sprout Technology Co., Ltd. Silicon containing organic fluorescent materials
CN109553608B (zh) 2017-09-26 2020-12-08 北京大学 一类五元六元杂环化合物及其制备方法和治疗肿瘤的用途
CN107827809A (zh) 2017-10-31 2018-03-23 长春海谱润斯科技有限公司 一种芳胺化合物及其有机发光器件
KR20200100628A (ko) 2017-12-22 2020-08-26 디아이씨 가부시끼가이샤 중합성 액정 조성물 및 액정 표시 소자 그리고 중합성 화합물
EP3755697A4 (en) 2018-02-20 2021-10-27 Dana-Farber Cancer Institute, Inc. EGFR DEGRADATION AGENTS AND METHODS FOR USING THEM
CA3088561A1 (en) 2018-02-20 2019-08-29 Dana-Farber Cancer Institute, Inc. Degraders of egfr and methods of use thereof
CN116332916B (zh) 2018-03-29 2025-08-29 德山新勒克斯有限公司 用于有机电气元件的化合物、使用所述化合物的有机电气元件及其电子装置
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
IL302595A (en) 2018-04-13 2023-07-01 Arvinas Operations Inc Servalon ligands and bifunctional compounds containing them
WO2019222349A1 (en) 2018-05-15 2019-11-21 Dana-Farber Cancer Institute, Inc. Compounds for treating dengue virus infections and other infections
EP3820500A4 (en) 2018-07-13 2022-04-13 Teqla Therapeutics, Inc. USE OF BCL6 INHIBITORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
US20210226132A1 (en) 2018-07-17 2021-07-22 Hodogaya Chemical Co., Ltd. Organic electroluminescent element
CA3106239A1 (en) 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
MX2021004191A (es) 2018-10-15 2021-05-27 Nurix Therapeutics Inc Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
WO2020081695A1 (en) 2018-10-17 2020-04-23 Nikang Therapeutics, Inc. Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors
SG11202105256QA (en) 2018-11-21 2021-06-29 Accutar Biotechnology Inc Novel compounds having estrogen receptor alpha degradation activity and uses thereof
AU2019391016B2 (en) 2018-12-03 2025-05-29 Dana-Farber Cancer Institute, Inc. Small molecule degraders of helios and methods of use
WO2020118036A1 (en) 2018-12-06 2020-06-11 The Children's Medical Center Corporation Antibacterial compounds and uses thereof
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
KR102720178B1 (ko) 2019-01-02 2024-10-21 덕산네오룩스 주식회사 유기전기소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
US20220073471A1 (en) 2019-01-04 2022-03-10 Jiangsu Hengrui Medicine Co., Ltd. 6-oxo-1,6-dihydropyridazine derivative, preparation method therefor and medical use thereof
EP3922632A4 (en) 2019-02-07 2023-02-15 Korea Research Institute of Chemical Technology DEGRADATION AGENT THAT INDUCES DEGRADATION OF A TARGET EED PROTEIN, METHOD FOR ITS MANUFACTURE AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DISEASES ASSOCIATED WITH EED, EZH2 OR PRC2 USING SUCH AGENT AS THE ACTIVE SUBSTANCE
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US11389438B2 (en) 2019-02-25 2022-07-19 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
WO2020198435A1 (en) 2019-03-26 2020-10-01 The Regents Of The University Of Michigan Small molecule degraders of stat3
CN110092804A (zh) 2019-03-29 2019-08-06 广州盈升生物科技有限公司 一种含双环基团的嘌呤化合物及其制备方法
WO2020225398A1 (en) 2019-05-09 2020-11-12 Merck Patent Gmbh Aromatic compounds
CN112566905B (zh) 2019-05-10 2024-07-30 上海海雁医药科技有限公司 取代的苯基丙烯基吡啶类衍生物，其制法与医药上的用途
CN112010858B (zh) 2019-05-31 2023-07-18 四川海思科制药有限公司 一种btk抑制剂及其制备方法和药学上的应用
CN112047932B (zh) 2019-06-05 2022-11-08 中国药科大学 吡唑类脾酪氨酸激酶抑制剂及其制备方法与用途
JP7771497B2 (ja) 2019-06-10 2025-11-18 ワシントン・ユニバーシティ Ｓｗｅｌｌ１－ｌｒｒｃ８複合体調節物質
CN112513029B (zh) 2019-06-21 2023-10-24 上海翰森生物医药科技有限公司 含氮芳基磷氧化物类衍生物、其制备方法和应用
CN112125885B (zh) 2019-06-25 2026-03-17 中国药科大学 苯并吲哚类双功能分子衍生物及其应用
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
AU2020319005B2 (en) 2019-07-23 2026-01-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
US20230002371A1 (en) 2019-09-13 2023-01-05 Biotheryx, Inc. Ras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2021055756A1 (en) 2019-09-19 2021-03-25 The Regents Of The University Of Michigan Spirocyclic androgen receptor protein degraders
CN112552293A (zh) 2019-09-25 2021-03-26 珠海宇繁生物科技有限责任公司 一种protac小分子化合物及其应用
US20220372042A1 (en) 2019-10-03 2022-11-24 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
WO2021078227A1 (zh) 2019-10-25 2021-04-29 江苏恒瑞医药股份有限公司 稠合杂芳基类衍生物、其制备方法及其在医药上的应用
AU2020384066B2 (en) 2019-11-15 2025-10-30 Green Cross Corporation Novel derivatives having 2,3-dihydro-1H-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
JP7629459B2 (ja) 2019-11-19 2025-02-13 ブリストル－マイヤーズ スクイブ カンパニー Ｈｅｌｉｏｓタンパク質の阻害剤として有用な化合物
CN110885332B (zh) 2019-12-06 2022-03-18 中国人民解放军第二军医大学 一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用
US20230099031A1 (en) 2019-12-17 2023-03-30 Orionis Biosciences, Inc. Bifunctional agents for protein recruitment and/or degradation
WO2021126973A1 (en) 2019-12-17 2021-06-24 Orionis Biosciences, Inc. Compounds modulating protein recruitment and/or degradation
CN114829342A (zh) 2019-12-23 2022-07-29 上海济煜医药科技有限公司 一种蛋白降解剂化合物的制备方法和应用
JP2023510279A (ja) 2020-01-09 2023-03-13 ワシントン・ユニバーシティ インフラマソーム活性化の抑制
EP4112054A4 (en) 2020-02-28 2024-03-27 Shanghai Runshi Medical Technology Co., Ltd USE OF CSF-1R KINASE INHIBITORS
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
KR20210122163A (ko) 2020-03-27 2021-10-08 (주) 업테라 Plk1의 선택적 분해를 유도하는 피라졸로퀴나졸린 유도체 화합물
CN113509557A (zh) 2020-04-09 2021-10-19 嘉兴优博生物技术有限公司 靶向蛋白酶降解平台(ted)
CA3172589A1 (en) 2020-05-21 2021-11-25 Dana-Farber Cancer Institute, Inc. Piperidine-2,6-diones as small molecule degraders of helios and methods of use
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
IL301690A (en) 2020-10-16 2023-05-01 Dana Farber Cancer Inst Inc Piperidinyl small molecule degraders of helios and methods of use
CN112430216B (zh) 2020-11-23 2022-12-09 六夫丁作物保护有限公司 消杀剂和农药中苯并咪唑类化合物的制备方法
CN113013346B (zh) 2021-02-25 2023-06-27 上海弗屈尔光电科技有限公司 三元组合物和含有该组合物的有机电致发光元件及应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020012334A1 (en) * 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
WO2020012337A1 (en) * 2018-07-10 2020-01-16 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases

Also Published As

Publication number Publication date
IL309666A (en) 2024-02-01
US20240246935A1 (en) 2024-07-25
AU2022306297A1 (en) 2024-02-08
KR20240035820A (ko) 2024-03-18
US20230265071A1 (en) 2023-08-24
WO2023283425A1 (en) 2023-01-12
EP4367112A1 (en) 2024-05-15
MX2024000313A (es) 2024-03-06
TW202317546A (zh) 2023-05-01
US11878968B2 (en) 2024-01-23
CA3226162A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
JP2024529298A (ja) Ｉｋｚｆ２を調節するアリール化合物及び医薬組成物
TWI877136B (zh) 化合物、組合物及方法
EP4366835A1 (en) Heterocycloalkyl and heteroaryl compounds and pharmaceutical compositions that modulate ikzf2
CN121605110A (zh) 取代杂环化合物及其用途
WO2023239629A1 (en) Compounds and pharmaceutical compositions that degrade cdk2
KR20240033704A (ko) 지모의 사르사사포게닌 구조를 기반으로 하는 유도체, 약물 조성물 및 그의 용도
US20240287037A1 (en) Cycloalkyl compounds and pharmaceutical compositions that modulate ikzf2
KR20170132278A (ko) 암 치료에 유용한 1-(사이클로) 알킬 피리딘-2-온의 트리사이클릭 융합 유도체
CN117003730A (zh) 取代嘧啶酰肼类化合物及其制备方法和应用
KR20160118359A (ko) 2-(아미노 에틸옥시) 벤조산 유도체의 고리화에 의한 3,4-디히드로-1,4-벤족사제핀-5(2h)-온 유도체의 제조
TW202410889A (zh) 調節ikzf2之環烷基化合物及醫藥組合物
JP2026502995A (ja) Ｉｋｚｆ２を調節するスピロシクロアルキル化合物および医薬組成物
CN117836288A (zh) 调节ikzf2的芳基化合物和医药组合物
TW201617326A (zh) （ｓ）－１－（（２ｒ，３ｒ，４ｓ，５ｓ）－５－烯丙－３－甲氧－４－（對甲苯磺醯甲基）四氫呋喃－２－基）－３－氨基丙－２－醇之結晶衍生物
JP2025525340A (ja) Ｓｗｉ／ｓｎｆ－ｒｅｌａｔｅｄ ｍａｔｒｉｘ－ａｓｓｏｃｉａｔｅｄ ａｃｔｉｎ－ｄｅｐｅｎｄｅｎｔ ｒｅｇｕｌａｔｏｒ ｏｆ ｃｈｒｏｍａｔｉｎ ｓｕｂｆａｍｉｌｙ ａを分解する化合物および医薬組成物
CN121620368A (zh) 降解swi/snf相关基质相关联肌动蛋白依赖性染色质调控因子a亚家族的化合物和药物组合物
CN121646466A (zh) 降解swi/snf相关基质相关联肌动蛋白依赖性染色质调控因子a亚家族的化合物和药物组合物
AU2024298553A1 (en) Salts and solid forms of compounds that modulate ikzf2
WO2023196512A1 (en) Propargyl compounds and pharmaceutical compositions that modulate brd4
CN121752556A (zh) 降解swi/snf相关基质相关联肌动蛋白依赖性染色质调控因子a亚家族的化合物和药物组合物
JP2015048326A (ja) 光学活性カルビノール化合物の製造法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250707

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260331